Vir Biotechnology (VIR) Set to Announce Quarterly Earnings on Thursday

Vir Biotechnology (NASDAQ:VIR) will issue its quarterly earnings data after the market closes on Thursday, October 31st. Analysts expect the company to announce earnings of ($0.96) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.13). The firm had revenue of $3.08 million for the quarter, compared to the consensus estimate of $7.53 million. Vir Biotechnology had a negative net margin of 612.40% and a negative return on equity of 30.93%. The business’s revenue for the quarter was down 19.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.45) earnings per share. On average, analysts expect Vir Biotechnology to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vir Biotechnology Price Performance

Shares of NASDAQ VIR opened at $7.52 on Thursday. Vir Biotechnology has a 1 year low of $7.12 and a 1 year high of $13.09. The firm has a 50-day simple moving average of $7.89 and a two-hundred day simple moving average of $8.94. The company has a market cap of $1.02 billion, a P/E ratio of -1.88 and a beta of 0.46.

Insiders Place Their Bets

In other Vir Biotechnology news, Director Janet Napolitano sold 12,190 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $7.80, for a total transaction of $95,082.00. Following the transaction, the director now directly owns 11,616 shares in the company, valued at $90,604.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 15.60% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on VIR. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research report on Tuesday, August 20th. Barclays raised their price target on shares of Vir Biotechnology from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $36.80.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).